Amerikanische Gesellschaft für Hirudotherapie

Heparin Versus Bivalirudin in Pediatric Patients Assisted With Mechanical Circulatory Support: A Retrospective Before-and-after Study

Retrospective study published in Journal of Cardiothoracic and Vascular Anesthesia (2025)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Observational studyKlinische StudienArzneimittelentwicklungGiorni C et al. · Journal of Cardiothoracic and Vascular Anesthesia, 2025

Abstract

OBJECTIVES: Children assisted with mechanical circulatory support experience bleeding and thrombotic complications that may depend upon anticoagulation strategies. The primary aim of this study was to compare the incidence of thrombotic events in pediatric heart failure patients assisted with mechanical circulatory support with the use of bivalirudin versus heparin anticoagulation. A secondary aim was to compare the percentage of out-of-range partial thromboplastin time values between these anticoagulants. DESIGN: Retrospective cohort study. SETTING: Tertiary pediatric cardiac intensive care unit. PARTICIPANTS: Pediatric patients undergoing mechanical circulatory support for cardiac failure. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: A total of 36 pediatric patients on mechanical support treated with either heparin (n.18) or bivalirudin (n.18) during the first 30 days of intensive care unit admission were compared. Bivalirudin group data were retrieved from February 2018 to August 2020 while data on the heparin group were extrapolated from 2015 to 2017. A comparison of anticoagulation was conducted specifically in EXCOR Berlin Heart and extracorporeal membrane oxygenation patients. Berlin Heart patients showed 1 (12.5%) versus 8 (80%) thrombotic episodes in the bivalirudin and heparin groups, respectively (p = 0.005), 0 and 3 (30%) cerebrovascular events, and 0 versus 3 (30%) death episodes, respectively (p = 0.054). In extracorporeal membrane oxygenation patients, the bivalirudin and heparin groups showed 0 versus 1 (8.3%) patient with a thrombosis episode (p = 0.40), 0 and 0 cerebrovascular events, and 5 (50%) versus 3 (25%) death episodes, respectively (p = 0.169). The number of out-of-range partial thromboplastin time values was higher in the heparin group both in Berlin Heart and extracorporeal membrane oxygenation patients (p < 0.0001). CONCLUSIONS: In a cohort of children with heart failure, bivalirudin use was associated with a reduction in thrombotic events in Berlin Heart patients compared with heparin over a period of 30 days.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleComparative Study
Indexed MeSH termsHumansHirudinsRetrospective StudiesPeptide FragmentsMaleFemaleRecombinant ProteinsHeparinChildChild, PreschoolAntithrombinsExtracorporeal Membrane Oxygenation

Zusammenfassung

Berlin Heart EXCOR pediatric patients showed dramatically lower thrombotic event rates with bivalirudin (12.5%) vs heparin (80%); aPTT values were more often out-of-range with heparin.

Warum dies für die Hirudotherapie relevant ist

This retrospective cohort study compared bivalirudin versus heparin anticoagulation in 36 pediatric patients on mechanical circulatory support (Berlin Heart EXCOR or extracorporeal membrane oxygenation) during the first 30 intensive care unit days. Berlin Heart patients showed significantly fewer thrombotic episodes with bivalirudin (12.5% vs. 80%, p=0.005) and fewer out-of-range partial thromboplastin time values (p<0.0001); extracorporeal membrane oxygenation subgroup differences were not statistically significant for thrombosis or mortality. The authors conclude bivalirudin use was associated with reduced thrombotic events in Berlin Heart patients compared with heparin. The abstract does not mention hirudin, leeches, leech therapy, or the leech secretome, so no direct connection to hirudotherapy is established. The study is a single-center retrospective comparison with 18 patients per group.

Zitation

Heparin Versus Bivalirudin in Pediatric Patients Assisted With Mechanical Circulatory Support: A Retrospective Before-and-after Study.

Giorni C et al. · Journal of Cardiothoracic and Vascular Anesthesia, 2025

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.